首页> 外文期刊>Critical care : >Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia
【24h】

Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia

机译:适当的抗菌治疗对从呼吸机相关的气管支气管炎向呼吸机相关的肺炎过渡的影响

获取原文
       

摘要

IntroductionTwo small randomized controlled trials have suggested beneficial effects of antibiotic treatment in patients with ventilator-associated tracheobronchitis (VAT). The primary aim of this study is to determine the impact of appropriate antibiotic treatment on transition from VAT to ventilator-associated pneumonia (VAP) in critically ill patients. The secondary objective was to determine the incidence of VAP in patients with VAT.MethodsThis was a prospective observational multicenter study. All patients with a first episode of VAT were eligible. Patients with tracheostomy at intensive care unit (ICU) admission, and those with VAP prior to VAT were excluded. VAT was defined using all the following criteria: fever?>?38°C with no other cause, purulent tracheal secretions, positive tracheal aspirate (≥105?cfu/mL), and absence of new infiltrate on chest X ray. Only VAP episodes diagnosed during the 96?h following VAT, and caused by the same bacteria, were taken into account. Antibiotic treatment was at the discretion of attending physicians. Risk factors for transition from VAT to VAP were determined using univariate and multivariate analysis. All variables from univariate analysis with P values <0.1 were incorporated in the multivariate logistic regression analysis.ResultsOne thousand seven hundred and ten patients were screened for this study. Eighty-six, and 123 patients were excluded for tracheostomy at ICU admission, and VAP prior to VAT; respectively. One hundred and twenty two (7.1%) patients were included. 17 (13.9%) patients developed a subsequent VAP. The most common microorganisms in VAT patients were Pseudomonas aeruginosa (30%), Staphylococcus aureus (18%), and Acinetobacter baumannii (10%). Seventy-four (60%) patients received antimicrobial treatment, including 58 (47.5%) patients who received appropriate antimicrobial treatment. Appropriate antibiotic treatment was the only factor independently associated with reduced risk for transition from VAT to VAP (OR [95% CI] 0.12[0.02-0.59], P?=?0.009). The number of patients with VAT needed to treat to prevent one episode of VAP, or one episode of VAP related to P. aeruginosa was 5, and 34; respectively.ConclusionsAppropriate antibiotic treatment is independently associated with reduced risk for transition from VAT to VAP.
机译:前言两项小型的随机对照试验表明,抗生素治疗对呼吸机相关性气管支气管炎(VAT)有益。这项研究的主要目的是确定危重病患者适当的抗生素治疗对从增值税过渡到呼吸机相关性肺炎(VAP)的影响。次要目的是确定VAT患者中VAP的发生率。方法这是一项前瞻性观察性多中心研究。所有首发增值税的患者均符合条件。重症监护病房(ICU)入院时行气管切开术的患者,以及在增值税前行VAP的患者均被排除在外。使用以下所有标准定义增值税:发烧≥38°C,无其他原因,气管分泌物化脓,气管抽吸物阳性(≥105?cfu / mL),并且在X射线胸片上没有新的浸润。仅考虑在增值税后96小时内由相同细菌引起的VAP发作。抗生素治疗由主治医生决定。使用单变量和多变量分析确定了从增值税过渡到VAP的风险因素。将单因素分析中P值<0.1的所有变量都纳入多元logistic回归分析。结果筛选了177例患者。在ICU入院时行气管切开术的患者为86例,在VAT之前行VAP的患者为123例;分别。包括一百二十二(7.1%)名患者。 17名(13.9%)患者发生了随后的VAP。增值税患者中最常见的微生物是铜绿假单胞菌(30%),金黄色葡萄球菌(18%)和鲍曼不动杆菌(10%)。七十四(60%)位患者接受了抗菌治疗,其中58位(47.5%)患者接受了适当的抗菌治疗。适当的抗生素治疗是唯一与降低从增值税过渡到VAP的风险相关的因素(OR [95%CI] 0.12 [0.02-0.59],P = 0.009)。需要进行预防一次VAP发作或与铜绿假单胞菌有关的VAP发作需要治疗的VAT患者人数分别为5和34;结论适当的抗生素治疗与从VAT过渡到VAP的风险降低独立相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号